Trial 7H-17-2

A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (MK3475-689) (Keynote 689) (LA HNSCC)

Type: Treatment
Phase: Phase III
Status: Open to Accrual
Treatments: Chemotherapy: Systemic, Immunotherapy
Randomized: Yes
Defintions of terms and FAQ about clinical trials.

Trial Leaders/Researchers: Jorge Nieva, M.D.
Other Trial Staff: Victoria Amran, D.M., Grace Facio, Coordinator, Gina Tse, Coordinator, Eduardo Mejia, D.M., Laurie De Oliveira, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov

For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.